Tendon disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:07:24 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Tendon disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Botulinum Toxin for Patients with Degenerative Rotator Cuff Tendinopathy https://clinicaltrials.eu/trial/study-on-botulinum-toxin-for-patients-with-degenerative-rotator-cuff-tendinopathy/ Wed, 29 Apr 2026 15:01:36 +0000 https://clinicaltrials.eu/trial/study-on-botulinum-toxin-for-patients-with-degenerative-rotator-cuff-tendinopathy/ This clinical trial is focused on studying the effects of a treatment for degenerative rotator cuff disease, a condition affecting the shoulder. The treatment being tested is called Xeomin, which contains a substance known as botulinum toxin. This toxin is used in various medical treatments to help reduce muscle activity and pain.

The purpose of the study is to evaluate how effective botulinum toxin is in treating shoulder pain and disability caused by degenerative rotator cuff disease. Participants in the study will receive either the Xeomin treatment or a placebo, which is a substance with no active medication. The study will monitor changes in shoulder pain and function over a period of one month, using a tool called the Shoulder Pain and Disability Index (SPADI) to measure outcomes.

Throughout the study, participants will be asked to attend regular visits to assess their progress. The study will also track any changes in pain levels and the use of pain medication over a three-month period. The goal is to determine if the treatment can provide relief from shoulder pain and improve daily function for those with degenerative rotator cuff disease.

]]> Study on the Safety and Effects of NGI226 Microparticles for Patients with Achilles Tendinopathy https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-ngi226-microparticles-for-patients-with-achilles-tendinopathy/ Wed, 29 Apr 2026 14:25:01 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-ngi226-microparticles-for-patients-with-achilles-tendinopathy/ This clinical trial is focused on studying Achilles tendinopathy, a condition that causes pain and swelling in the tendon at the back of the ankle. The study will evaluate a new treatment called NGI226, which is a powder mixed into a liquid and injected near the affected tendon. The purpose of the study is to assess the safety and initial effectiveness of this treatment in helping the tendon heal.

Participants in the study will receive either the NGI226 treatment or a placebo, which looks like the treatment but does not contain the active substance. The study is designed to be “blinded,” meaning neither the participants nor the researchers will know who receives the actual treatment or the placebo. This helps ensure the results are unbiased. The study will monitor participants for any side effects and changes in their symptoms over time.

The trial will involve regular check-ups to assess the condition of the tendon and overall health. This includes looking at changes in pain, swelling, and other symptoms, as well as conducting tests like blood work and heart monitoring. The study aims to provide valuable information on whether NGI226 can be a safe and effective option for people suffering from Achilles tendinopathy.

]]>